Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus Resistant EBV CTL for PTLD After Solid Organ Transplant
NCT03131934Phase 1Completed
- Sponsor
- University College London
- Start
- May 2019
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Post-transplant lymphoproliferative disease (PTLD), sponsored by University College London. Primary endpoints: Toxicity at 6 weeks and Persistence and frequency of circulating EBV CTL at 12 months. Started May 2019; status: completed.
02
Conditions
Post-transplant lymphoproliferative disease (PTLD)
Beyond the preview
Go deeper on NCT03131934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131934.